Research programme: anticancer potentiating agents - Oncore TherapeuticsAlternative Names: Anticancer potentiating agents research programme; Potentiating agents - Oncore Therapeutics; PTA project
Latest Information Update: 06 Aug 2009
At a glance
- Originator Pfizer
- Class Carbamates; Steroids
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 May 2005 Preclinical trials in Cancer in Switzerland (Parenteral)
- 27 May 2005 Preclinical trials in Cancer in Switzerland (PO)